Rising Liver Cancer Cases in the US Linked to Alcohol-Associated Liver Disease and MASLD

From 2000 to 2021, primary liver cancer incidences and deaths in the US increased by more than 100%, driven by rapid growth in Alcohol-Associated Liver Disease (ALD) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

In other developments, the FDA granted Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis (PBC), following positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLD’s The Liver Meeting.

Additionally, a study identified antibodies linked to PSC disease severity and transplant-free survival, suggesting the potential value of anti-gliadin and anti-F-actin IgA for risk stratification in patients with primary sclerosing cholangitis.

The Hepatology Month in Review for December 2024 highlighted hepatic FDA news and the latest research in viral hepatitis and MASH.